Variation in melphalan dosing in myeloma patients undergoing high-dose chemotherapy and autotransplantation

被引：0
|
作者：
Mehta, J.
Carson, K. R.
Trifilio, S.
Vickrey, E.
Allen, S.
Singhal, S.
机构：
[1] NW Mem Hosp, Chicago, IL 60611 USA
[2] NW Mem Fac Fdn, Chicago, IL USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2008年 / 26卷 / 15期
关键词：
D O I：
10.1200/jco.2008.26.15_suppl.7047
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
7047
引用
收藏
页数：1
相关论文
共 50 条
  • [1] Feasibility of administering high-dose melphalan (HDM) with autotransplantation in myeloma patients on dialysis.
    Sirohi, B
    Powles, R
    Kulkarni, S
    Menon, A
    Ahmed, T
    Saso, R
    Goyal, S
    Rudin, C
    Treleaven, J
    BLOOD, 2001, 98 (11) : 399B - 399B
  • [2] Response to induction chemotherapy is not essential to obtain survival benefit from high-dose melphalan and autotransplantation in myeloma
    Singhal, S
    Powles, R
    Sirohi, B
    Treleaven, J
    Kulkarni, S
    Mehta, J
    BONE MARROW TRANSPLANTATION, 2002, 30 (10) : 673 - 679
  • [3] Response to induction chemotherapy is not essential to obtain survival benefit from high-dose melphalan and autotransplantation in myeloma
    S Singhal
    R Powles
    B Sirohi
    J Treleaven
    S Kulkarni
    J Mehta
    Bone Marrow Transplantation, 2002, 30 : 673 - 679
  • [4] Response to induction chemotherapy is not essential to obtain survival benefit from high-dose melphalan and autotransplantation in myeloma
    Singhal, S
    Powles, R
    Sirohi, B
    Kulkarni, S
    Treleaven, J
    Goyal, S
    Sankpal, S
    Rao, S
    Saso, R
    Mehta, J
    BONE MARROW TRANSPLANTATION, 2002, 29 : S103 - S103
  • [5] High-dose melphalan in patients with multiple myeloma
    Moreau, P
    Le Bonniec, M
    Harousseau, JL
    BULLETIN DU CANCER, 1999, 86 (03) : 283 - 288
  • [6] Change in antiemetic prophylaxis in patients with myeloma undergoing conditioning with high-dose melphalan
    Skagerlind, L.
    Liljeholm, M.
    Astrom, F.
    Lindkvist, U.
    BONE MARROW TRANSPLANTATION, 2012, 47 : S491 - S491
  • [7] Response to induction chemotherapy is not essential to obtain survival benefit from high-dose melphalan and autotransplantation in myeloma.
    Singhal, S
    Powles, R
    Sirohi, B
    Treleaven, J
    Mehta, J
    BLOOD, 2001, 98 (11) : 816A - 816A
  • [8] Outpatient high-dose melphalan in multiple myeloma patients
    Kassar, Mohamad
    Medoff, Erin
    Seropian, Stuart
    Cooper, Dennis L.
    TRANSFUSION, 2007, 47 (01) : 115 - 119
  • [9] Pharmacodynamics of High-Dose Melphalan in Myeloma
    Nath, C. E.
    Joshua, D.
    Kerridge, I.
    Kwan, Y. L.
    Shaw, P. J.
    Trotman, J.
    Zeng, L.
    Presgrave, P.
    Tiley, C.
    McLachlan, A.
    Gurney, H.
    Earl, J.
    CLINICAL LYMPHOMA & MYELOMA, 2009, 9 : S34 - S35
  • [10] MULTIPLE-MYELOMA - COMPLETE REMISSION WITH HIGH-DOSE MELPHALAN CHEMOTHERAPY
    RICHARDS, F
    COLEMAN, M
    COOPER, MR
    BALLARD, WP
    CANCER INVESTIGATION, 1985, 3 (01) : 15 - 21
12345